Metabolik sendromlu obez hastalarda serum ürik asit düzeyleri

Amaç: Bu çalışmada; obez hastalarda metabolik sendrom görülme sıklığının belirlenmesi ve metabolik sendromlu obez hastalarda serum ürik asit düzeylerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Retrospektif çalışmaya Kasım 2018-Şubat 2020 tarihleri arasında Sağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi Obezite Merkezinde takipli 270 obez hasta dahil edildi. Metabolik sendrom olan ve olmayan şeklinde iki gruba ayrılan hastalar serum ürik asit düzeyleri ve diğer çalışma parametreleri açısından karşılaştırıldı. Bulgular: Hastaların %92,6’sı kadın, %7,4'ü erkekti. Ortalama yaş 51,8±9,6 (21–73) yıl idi. 141 hastada (%52,22) metabolik sendrom vardı. Metabolik sendrom olan hastalarda kilo, vücut kitle indeksi, bel/kalça oranı ölçümleri anlamlı yüksek bulundu. Metabolik sendrom parametrelerinin yanı sıra glikozillenmiş hemoglobin, açlık insülini, insülin direnci ve ürik asit düzeyleri de metabolik sendrom olan grupta anlamlı yüksekti. Metabolik sendrom olan hastalarda ürik asit ile bel çevresi, açlık insülini ve insülin direnci arasında istatistiksel olarak anlamlı pozitif bir korelasyon saptandı. Çok değişkenli lojistik regresyon analizi; ürik asitin diğer parametrelerden bağımsız olarak metabolik sendrom riskini arttırdığını gösterdi. Sonuç: Obez hastalarda metabolik sendrom görülme sıklığı artmaktadır ve metabolik sendromun eşlik ettiği obez hastalarda serum ürik asit düzeyleri yükselmektedir. Ayrıca bu hastalarda serum ürik asit düzeyleri ile bel çevresi ve insülin direnci arasında pozitif korelasyon görülmektedir. Bu bağlamda, özellikle abdominal obezite ve insülin direnci tespit edilen metabolik sendromlu obez hastalar kardiyovasküler hastalık risk belirteci olarak değerlendirilen hiperürisemi açısından taranmalıdır.

Anahtar Kelimeler:

Metabolik sendrom, obezite, ürik asit

Serum uric acid levels in obese patients with metabolic syndrome

Purpose: The aim of this study was to determine the frequency of metabolic syndrome in obese patients and to evaluate serum uric acid levels in obese patients with metabolic syndrome. Materials and Methods: The retrospective study included 270 obese patients with follow-up at the Obesity Center of Health Sciences University Antalya Training and Research Hospital between November 2018 and February 2020. Patients who were divided into two groups with and without metabolic syndrome were compared in terms of serum uric acid levels. Results: Of the patients 92,6% were female and 7,4% were male. The average age was 51,8±9,6 years. 141 patients (52,22%) had metabolic syndrome. Weight, body mass indexe, waist/hip ratio were significantly higher in patients with metabolic syndrome. In addition to metabolic syndrome parameters, glycosylated hemoglobin, fasting insulin, insulin resistance and uric acid levels were also significantly higher in the group with metabolic syndrome. A statistically significant positive correlation was found between uric acid and waist circumference, fasting insulin and insulin resistance in patients with metabolic syndrome. Multivariate logistic regression analysis showed that uric acid increased the risk of metabolic syndrome regardless of other parameters. Conclusion: The frequency of metabolic syndrome increases in obese patients, and serum uric acid levels increase in obese patients accompanied by metabolic syndrome. In addition, there is a positive correlation between serum uric acid levels and waist circumference and insulin resistance in these patients. Especially obese patients with metabolic syndrome accompanying with abdominal obesity and insülin resistance should be screened for hyperuricemia, which is considered as a cardiovascular disease risk marker.

PDF

___

1. TEMD Obezite, Lipid Metabolizması, Hipertansiyon Çalışma Grubu. Obezite Tanı ve Tedavi Kılavuzu 2019, 8. baskı. Ankara, Türkiye Endokrinoloji ve Metabolizma Derneği, 2019.
2. Kim SK. Interrelationship of uric acid, gout, and metabolic syndrome: Focus on hypertension, cardiovascular disease, and insulin resistance. J Rheum Dis. 2018;25:19-27.
3. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev. 2005;6:283-96.
4. Balkan F. Metabolik sendrom. Ankara Medical Journal. 2013;13:85-90.
5. TEMD Metabolik Sendrom Çalışma Grubu. Metabolik Sendrom Kılavuzu 2009. Ankara, Türkiye Endokrinoloji ve Metabolizma Derneği, 2009.
6. International Diabetes Federation. The IDF Consensus Worldwide Definition of The Metabolic Syndrome. Brussels, International Diabetes Federation, 2006.
7. Aguilar-Salinas CA, Viveros-Ruiz T. Recent advances in managing/understanding the metabolic syndrome. F1000Res. 2019;8:370-9.
8. Pyrah LN. Renal Calculus. Berlin, Springer, 1979.
9. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858- 62.
10. Batta A. Uric acid is a significant antioxidant. Eur J Pharm Med Res. 2016;3:242-8.
11. Settle T, Klandorf H. The role of uric acid as an antioxidant in selected neurodegenerative disease pathogenesis: A short review. Brain Disord Ther. 2014;3:129-33.
12. Ayyıldız SN. Ürik asit yüksekliğinin analizi. Journal of Academic Research in Medicine. 2016;6:74-7.
13. Choi HK, McCormick N, Lu N, Rai SK, Yokose C, Zhang Y. Population impact attributable to modifiable risk factors for hyperuricemia. Arthritis Rheumatol. 2020;72:157-65.
14. Kayhan Tetik B, Baydar Artantaş A, İnce B, Üstü Y. Üçüncü atakta tanı konulan bir gut vakası. Ankara Medical Journal. 2012;12:100-2.
15. Akbaş EM, Özçiçek A, Özçiçek F, Demirtaş L, Timuroğlu A, Güngör A, Akbaş N. Metabolik olarak sağlıklı ve sağlıksız obez hastalarda ürik asit seviyeleri. Dicle Tıp Dergisi. 2014;41:676-80.
16. Ali N, Perveen R, Rahmen S, Mahmood S, Rahman S, Islam S et al. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. PLoS One. 2018;13:e0206850.
17. Remedios C, Shah M, Bhasker AG, Lakdawala M. Hyperuricemia: a reality in the Indian obese. Obes Surg. 2012;22:945-8.
18. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48:1031-6.
19. Huda N, Hossain S, Rahman M, Karim MR, Islam K, Mamun AA et al. Elevated levels of plasma uric acid and its relation to hypertension in arsenic-endemic human individuals in Bangladesh. Toxicol Appl Pharmacol. 2014;281:11-8.
20. Desai RJ, Franklin JM, Spoendlin-Allen J, Solomon DH, Danaei G, Kim SC. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One. 2018;13(2):e0193622.
21. Wang H, Zhang H, Sun L, Guo W. Roles of hyperuricemia in metabolic syndrome and cardiackidney-vascular system diseases. Am J Transl Res. 2018;10:2749-63.
22. Pereira SS, Alvarez Leite-JI. Low-Grade Inflammation, obesity, and diabetes. Curr Obes Rep. 2014;3:422-31.
23. Cooke AA, Connaughton RM, Lyons CL, McMorrow AM, Roche HM. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur J Pharmacol. 2016;785:207- 14.
24. Zhou Y, Zhao M, Pu Z, Xu G, Li X. Relationship between oxidative stress and inflammation in hyperuricemia. Medicine (Baltimore). 2018;97:e13108.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
27. Solak B, Sevimli Dikicier B, Erdem T. Metabolik sendromlu psöriazis hastalarında ürik asitin rolü. Turk Arch Dermatol Venereol. 2017;51:37-40.
28. Suliga E, Koziel D, Gluszek S. Prevalence of metabolic syndrome in normal weight individuals. Ann Agric Environ Med. 2016;23:631-35.
29. Duan Y, Liang W, Zhu L, Zhang T, Wang L, Nie Z et al. Association between serum uric acid levels and obesity among university students. Nutr Hosp. 2015;31:2407-11.
30. Mukhopadhyay P, Ghosh S, Pandit K, Chatterjee P, Majhi B, Subhankar ChowdhuryS. Uric acid and its correlation with various metabolic parameters: A population-based study. Indian J Endocrinol Metab. 2019;23:134-9.
31. Li L, Song Q, Yang X. Lack of associations between elevated serum uric acid and components of metabolic syndrome such as hypertension, dyslipidemia, and T2 DM in overweight and obese Chinese adults. J Diabetes Res. 2019; 2019: 3175418..
32. Kim IY, Han KD, Kim DH, Eun Y, Cha HS, Koh EM, et al. Women with metabolic syndrome and general obesity are at a higher risk for significant hyperuricemia compared to men. J Clin Med. 2019;8:837.
33. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B. 2007;8(8):593-8.
34. Lee WS, Kang TS, Lee YH, Han MK. Assessment of association between metabolic syndrome and serum uric acid level in subjects who visited the health promotion center. Korean J Fam Pract. 2017;7:207- 12.
35. Ciarla S, Struglia M, Giorgini P, Striuli R, Necozione S, Properzi G et al. Serum uric acid levels and metabolic syndrome. Arch Physiol Biochem. 2014;120:119-22.
36. Yaday D, Lee ES, Kim HM, Lee EY, Choi E, Chung CH. Hyperuricemia as a potential determinant of metabolic syndrome. Lifestyle Med. 2013;3:98-106.
37. Han T, Lan L, Qu R, Xu Q, Jiang R, Na L et al. Temporal relationship between hyperuricemia and insulin resistance and its impact on future risk of hypertension. Hypertension. 2017;70:703-11.
38. Shirasawa T, Ochiai H, Yoshimoto T, Nagahama S, Watanabe A, Yoshida R et al. Cross-sectional study of associations between normal body weight with central obesity and hyperuricemia in Japan. BMC Endocr Disord. 2020;20:2.